Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BBIO NASDAQ:BPMC NASDAQ:CPRX NASDAQ:VRNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBIOBridgeBio Pharma$45.66-1.1%$40.73$21.72▼$48.68$8.77B1.152.85 million shs1.59 million shsBPMCBlueprint Medicines$129.46$122.43$73.04▼$129.65$8.36B0.891.55 million shsN/ACPRXCatalyst Pharmaceuticals$21.02-2.5%$23.08$15.34▼$26.58$2.63B0.661.31 million shs823,970 shsVRNAVerona Pharma PLC American Depositary Share$105.00+0.0%$90.51$18.51▼$105.30$8.93B0.247.54 million shs2.64 million shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBIOBridgeBio Pharma+0.92%-1.93%+9.53%+28.45%+68.02%BPMCBlueprint Medicines0.00%+0.14%+0.83%+50.38%+10.70%CPRXCatalyst Pharmaceuticals+3.21%+1.84%-2.49%-6.99%+22.84%VRNAVerona Pharma PLC American Depositary Share-0.06%+0.20%+8.14%+62.01%+366.86%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBBIOBridgeBio Pharma4.5992 of 5 stars4.51.00.03.92.93.30.6BPMCBlueprint Medicines1.1533 of 5 stars2.12.00.00.02.20.80.6CPRXCatalyst Pharmaceuticals4.9134 of 5 stars3.61.00.03.93.53.33.8VRNAVerona Pharma PLC American Depositary Share2.7693 of 5 stars2.15.00.00.03.72.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBBIOBridgeBio Pharma 3.00Buy$61.5034.69% UpsideBPMCBlueprint Medicines 2.24Hold$128.25-0.93% DownsideCPRXCatalyst Pharmaceuticals 3.25Buy$32.8356.20% UpsideVRNAVerona Pharma PLC American Depositary Share 2.15Hold$109.003.81% UpsideCurrent Analyst Ratings BreakdownLatest CPRX, VRNA, BBIO, and BPMC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/21/2025BBIOBridgeBio PharmaTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$66.007/14/2025BBIOBridgeBio PharmaPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$63.00 ➝ $68.007/14/2025BBIOBridgeBio PharmaJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$70.007/14/2025VRNAVerona Pharma PLC American Depositary ShareHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$90.00 ➝ $107.007/11/2025BBIOBridgeBio PharmaCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$58.00 ➝ $67.007/10/2025VRNAVerona Pharma PLC American Depositary SharePiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/10/2025VRNAVerona Pharma PLC American Depositary ShareWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/10/2025VRNAVerona Pharma PLC American Depositary ShareRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/10/2025VRNAVerona Pharma PLC American Depositary ShareWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold$138.00 ➝ $107.007/10/2025VRNAVerona Pharma PLC American Depositary ShareBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/9/2025VRNAVerona Pharma PLC American Depositary ShareCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold(Data available from 7/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBBIOBridgeBio Pharma$221.90M39.07N/AN/A($7.71) per share-5.92BPMCBlueprint Medicines$562.12M14.87N/AN/A$4.70 per share27.54CPRXCatalyst Pharmaceuticals$491.73M5.21$2.38 per share8.82$6.10 per share3.45VRNAVerona Pharma PLC American Depositary Share$42.28M211.42N/AN/A$2.56 per share41.02Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBBIOBridgeBio Pharma-$535.76M-$3.53N/AN/AN/A-524.25%N/A-94.43%8/5/2025 (Estimated)BPMCBlueprint Medicines-$67.09M-$2.47N/A199.17N/A-27.70%-64.60%-17.22%7/30/2025 (Estimated)CPRXCatalyst Pharmaceuticals$163.89M$1.5713.399.870.8836.91%42.45%36.59%8/6/2025 (Estimated)VRNAVerona Pharma PLC American Depositary Share-$173.42M-$2.00N/A3,500.00N/AN/A-69.65%-28.00%8/6/2025 (Estimated)Latest CPRX, VRNA, BBIO, and BPMC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025VRNAVerona Pharma PLC American Depositary Share$0.39N/AN/AN/A$68.24 millionN/A8/7/2025Q2 2025BPMCBlueprint Medicines-$0.54N/AN/AN/A$171.34 millionN/A8/6/2025Q2 2025CPRXCatalyst Pharmaceuticals$0.57N/AN/AN/A$140.42 millionN/A8/5/2025Q2 2025BBIOBridgeBio Pharma-$0.50N/AN/AN/A$98.46 millionN/A5/1/2025Q1 2025BPMCBlueprint Medicines-$0.42-$0.74-$0.32$0.01$158.31 million$149.41 million4/29/2025Q1 2025BBIOBridgeBio Pharma-$1.00-$0.88+$0.12-$0.88$57.14 million$36.74 million4/29/2025Q1 2025VRNAVerona Pharma PLC American Depositary Share-$0.22$0.27+$0.49-$0.16$41.47 million$98.65 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBBIOBridgeBio PharmaN/AN/AN/AN/AN/ABPMCBlueprint MedicinesN/AN/AN/AN/AN/ACPRXCatalyst PharmaceuticalsN/AN/AN/AN/AN/AVRNAVerona Pharma PLC American Depositary ShareN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBBIOBridgeBio PharmaN/A4.574.54BPMCBlueprint Medicines1.012.802.75CPRXCatalyst PharmaceuticalsN/A6.145.96VRNAVerona Pharma PLC American Depositary Share1.078.868.73Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBBIOBridgeBio Pharma99.85%BPMCBlueprint MedicinesN/ACPRXCatalyst Pharmaceuticals79.22%VRNAVerona Pharma PLC American Depositary Share85.88%Insider OwnershipCompanyInsider OwnershipBBIOBridgeBio Pharma18.20%BPMCBlueprint Medicines4.21%CPRXCatalyst Pharmaceuticals10.40%VRNAVerona Pharma PLC American Depositary Share4.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBBIOBridgeBio Pharma400189.88 million155.32 millionOptionableBPMCBlueprint Medicines64064.58 million61.86 millionOptionableCPRXCatalyst Pharmaceuticals80121.97 million109.29 millionOptionableVRNAVerona Pharma PLC American Depositary Share3085.13 million81.05 millionOptionableCPRX, VRNA, BBIO, and BPMC HeadlinesRecent News About These CompaniesVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Stake Trimmed by Dorsey Wright & AssociatesJuly 24 at 8:03 AM | marketbeat.comBank of New York Mellon Corp Takes Position in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)July 24 at 3:18 AM | marketbeat.comGW&K Investment Management LLC Sells 38,240 Shares of Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)July 23 at 5:05 AM | marketbeat.comPathway Capital Management LP Purchases Shares of 98,329 Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)July 21 at 10:13 AM | marketbeat.comVerdence Capital Advisors LLC Makes New Investment in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)July 21 at 4:47 AM | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Hits New 12-Month High - Here's What HappenedJuly 19, 2025 | marketbeat.comAtle Fund Management AB Acquires New Holdings in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)July 19, 2025 | marketbeat.comJennison Associates LLC Decreases Stock Position in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)July 19, 2025 | marketbeat.comCenterBook Partners LP Acquires Shares of 9,480 Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)July 18, 2025 | marketbeat.comYeomans Consulting Group Inc. Acquires New Position in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)July 18, 2025 | marketbeat.comBurns Matteson Capital Management LLC Makes New Investment in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)July 18, 2025 | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Sees Unusually-High Trading Volume - Here's What HappenedJuly 16, 2025 | marketbeat.comWeathering Market Uncertainty? Bet on VIPS, ALKT, FUTU & VRNA NowJuly 16, 2025 | zacks.comJacobson & Schmitt Advisors LLC Lowers Stock Position in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)July 16, 2025 | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Given "Neutral" Rating at HC WainwrightJuly 16, 2025 | americanbankingnews.comHC Wainwright & Co. Downgrades Verona Pharma plc - Depositary Receipt () (VRNA)July 15, 2025 | msn.comWhat Makes Verona Pharma PLC American Depositary Share (VRNA) a Strong Momentum Stock: Buy Now?July 15, 2025 | msn.comWhat Makes Verona Pharma PLC American Depositary Share (VRNA) a Strong Momentum Stock: Buy Now?July 15, 2025 | zacks.com$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Verona Pharma plc (NASDAQ: VRNA)July 14, 2025 | globenewswire.comPharmaceutical Stocks To Research - July 14thJuly 14, 2025 | marketbeat.comTimesSquare Capital Management LLC Acquires New Position in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)July 14, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCPRX, VRNA, BBIO, and BPMC Company DescriptionsBridgeBio Pharma NASDAQ:BBIO$45.66 -0.53 (-1.15%) Closing price 04:00 PM EasternExtended Trading$46.24 +0.59 (+1.28%) As of 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.Blueprint Medicines NASDAQ:BPMC$129.46 0.00 (0.00%) As of 07/18/2025Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.Catalyst Pharmaceuticals NASDAQ:CPRX$21.02 -0.55 (-2.55%) Closing price 04:00 PM EasternExtended Trading$21.22 +0.20 (+0.93%) As of 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.Verona Pharma PLC American Depositary Share NASDAQ:VRNA$105.00 +0.05 (+0.05%) Closing price 04:00 PM EasternExtended Trading$104.98 -0.03 (-0.02%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Krispy Kreme: A Meme Stock Sugar Rush or a Sustainable Treat? From Zero to Hero? Why GoPro's Rally Could Be More Than It Seems A Smokin’ Hot Entry Point for Chipotle Stock Opens in Q3 Alphabet’s Breakout Quarter Signals a New Leadership Phase Tesla Just Hit a Fork in the Road—Could the Bulls Lose Control? GE Vernova's Q2 Electrifies Stock, What's Next For This Top Name? Is Former Dividend Aristocrat AT&T a Buy After Q2 Earnings? What's Behind Opendoor Technologies' Rally? Is Meme Mania Back? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
